GoodRx flags medullary thyroid cancer and MEN2 syndrome, in yourself or your family, as reasons some GLP-1 weight loss medications shouldn't be used.
Recap by typeshit. Post by @goodrx on Instagram.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Retatrutide is still in clinical trials, yet Eli Lilly is already up against a web of black market sellers offering it online.
A general drug reference post pointing to tirzepatide basics like interactions and warnings. Evergreen material with no new development behind it.
Loading…